{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:52:33Z","timestamp":1793116353646,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ijid.2022.12.028","type":"journal-article","created":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T19:44:50Z","timestamp":1672083890000},"page":"223-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Lopinavir\/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial"],"prefix":"10.1016","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2334-5514","authenticated-orcid":false,"given":"Alexander M.","family":"Kaizer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan I.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2927-8239","authenticated-orcid":false,"given":"Jessica","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel M.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Jessica","family":"Cwik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly W.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan E.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5809-4060","authenticated-orcid":false,"given":"Michael S.","family":"Pulia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9300-3045","authenticated-orcid":false,"given":"Wesley H.","family":"Self","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clay","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick C.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6391-0448","authenticated-orcid":false,"given":"B. Taylor","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7136-5408","authenticated-orcid":false,"given":"Todd W.","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3297-2811","authenticated-orcid":false,"given":"Christopher J.","family":"Lindsell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adit A.","family":"Ginde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2022.12.028_bib0001","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 \u2013 Final Report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.12.028_bib0002","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe Covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.12.028_bib0003","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2022.12.028_bib0004","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Collaborative Group","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.12.028_bib0005","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.12.028_bib0006","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.12.028_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105252","article-title":"Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern","volume":"198","author":"Vangeel","year":"2022","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ijid.2022.12.028_bib0008","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMc2201933","article-title":"Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA.2","volume":"386","author":"Takashita","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.12.028_bib0009","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1473-3099(21)00751-9","article-title":"Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial","volume":"22","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2022.12.028_bib0010","first-page":"ciac180","article-title":"Molnupiravir and nirmatrelvir-ritonavir: oral Coronavirus Disease 2019 antiviral drugs","author":"Saravolatz","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.12.028_bib0011","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1111\/bph.15819","article-title":"How far are we from predicting multi-drug interactions during treatment for COVID-19 infection?","volume":"179","author":"Lozano","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ijid.2022.12.028_bib0012","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1038\/s41467-022-29858-5","article-title":"Comparing COVID-19-related hospitalization rates among individuals with infection-induced and vaccine-induced immunity in Israel","volume":"13","author":"Waxman","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijid.2022.12.028_bib0013","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/07853890.2022.2034936","article-title":"Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis","volume":"54","author":"Wen","year":"2022","journal-title":"Ann Med"},{"key":"10.1016\/j.ijid.2022.12.028_bib0014","doi-asserted-by":"crossref","first-page":"125","DOI":"10.15585\/mmwr.mm7104e1","article-title":"COVID-19 cases and hospitalizations by COVID-19 vaccination status and previous COVID-19 diagnosis\u2014California and New York, May\u2013November 2021","volume":"71","author":"Le\u00f3n","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ijid.2022.12.028_bib0015","doi-asserted-by":"crossref","first-page":"969","DOI":"10.7326\/M21-4905","article-title":"A longitudinal study of COVID-19 sequelae and immunity: baseline findings","volume":"175","author":"Sneller","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijid.2022.12.028_bib0016","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.7326\/M22-1492","article-title":"Understanding and improving recovery from COVID-19","volume":"175","author":"Hope","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijid.2022.12.028_bib0017","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses\u2014drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ijid.2022.12.028_bib0018","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with lopinavir\/ritonavir or interferon-\u03b21b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2022.12.028_bib0019","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1021\/acs.jcim.0c00179","article-title":"Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study","volume":"60","author":"Wang","year":"2020","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.ijid.2022.12.028_bib0020","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00399-20","article-title":"Compounds with therapeutic potential against novel respiratory 2019 coronavirus","volume":"64","author":"Martinez","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.12.028_bib0021","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3851\/IMP3002","article-title":"Combination therapy with lopinavir\/ritonavir, ribavirin and interferon-\u03b1 for Middle East respiratory syndrome","volume":"21","author":"Kim","year":"2016","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ijid.2022.12.028_bib0022","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bj.2020.11.005","article-title":"Lopinavir\/ritonavir: repurposing an old drug for HIV infection in COVID-19 treatment","volume":"44","author":"Magro","year":"2021","journal-title":"Biomed J"},{"key":"10.1016\/j.ijid.2022.12.028_bib0023","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1021\/acs.biochem.0c00160","article-title":"Why are lopinavir and ritonavir effective against the newly emerged coronavirus 2019? Atomistic insights into the inhibitory mechanisms","volume":"59","author":"Nutho","year":"2020","journal-title":"Biochemistry"},{"key":"10.1016\/j.ijid.2022.12.028_bib0024","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1021\/acs.jmedchem.5b01461","article-title":"An overview of severe acute respiratory syndrome\u2013coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy","volume":"59","author":"Pillaiyar","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijid.2022.12.028_bib0025","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.12.028_bib0026","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.12.028_bib0027","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(20)32013-4","article-title":"Lopinavir\u2013ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2022.12.028_bib0028","article-title":"Efficacy and safety of lopinavir\/ritonavir or arbidol in adult patients with mild\/moderate COVID-19: an exploratory randomized controlled trial","volume":"1","author":"Li","year":"2020","journal-title":"Med (N Y)"},{"key":"10.1016\/j.ijid.2022.12.028_bib0029","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.6468","article-title":"Effect of early treatment with hydroxychloroquine or lopinavir and ritonavir on risk of hospitalization among patients with COVID-19: the TOGETHER randomized clinical trial","volume":"4","author":"Reis","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijid.2022.12.028_bib0030","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s13063-022-06213-z","article-title":"Trial of Early antiviral Therapies during Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19: a summary of the protocol and analysis plan for a decentralized randomized controlled trial","volume":"23","author":"Kaizer","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.ijid.2022.12.028_bib0031","unstructured":"World health organization. WHO R&D Blueprint: informal consultation on prioritization of candidate therapeutic agents for use in novel coronavirus 2019 infection, Geneva, Switzerland, 24 January 2020. Geneva: World Health Organization; 2020."},{"key":"10.1016\/j.ijid.2022.12.028_bib0032","unstructured":"Harrell F. rmsb: Bayesian Regression Modeling Strategies. R package version 0.1.0 ed 2022. https:\/\/cran.r-project.org\/web\/packages\/rmsb\/index.html."},{"key":"10.1016\/j.ijid.2022.12.028_bib0033","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1093\/jac\/dkaa190","article-title":"Lopinavir\/ritonavir in COVID-19 patients: maybe yes, but at what dose?","volume":"75","author":"Baldelli","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2022.12.028_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.704767","article-title":"High dose lopinavir\/ritonavir does not lead to sufficient plasma levels to inhibit SARS-CoV-2 in hospitalized patients with COVID-19","volume":"12","author":"Karolyi","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijid.2022.12.028_bib0035","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01177-20","article-title":"Effect of systemic inflammatory response to SARS-CoV-2 on lopinavir and hydroxychloroquine plasma concentrations","volume":"64","author":"Marzolini","year":"2020","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222006658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222006658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:12:13Z","timestamp":1761120733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971222006658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":35,"alternative-id":["S1201971222006658"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2022.12.028","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lopinavir\/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2022.12.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}